neuroClues eyetracker
approvedplatform · high · Tue Apr 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Provide clinicians with objective, reproducible eye-movement biomarkers to quantify neurological exams, support earlier diagnosis, and monitor neurological disease progression.
Portable CE-marked Class IIa eye-tracking medical device that records eye movements and extracts neurological biomarkers.
Series A announced to bring AI-powered neurological biomarkers to clinicians in Europe and prepare U.S. entry.
Company states the product is CE-marked as a Class IIa medical device and targets neurological disorders including Parkinson's disease, Alzheimer's disease, multiple sclerosis, parkinsonian syndromes, and concussion-related impairments.
Antisaccade marker for freezing of gait in Parkinson's disease
exploratorybiomarker · medium
Evaluate antisaccade measures as a predictive marker for freezing of gait in Parkinson's disease.
Analysis of antisaccade eye-movement behavior and gait/gaze network connectivity.
Publication reported in 2021.
Publication title identifies antisaccade as a predictive marker for freezing of gait in Parkinson's disease and relates it to gait/gaze network connectivity.
Atypical Parkinson differential diagnosis program
undisclosedbiomarker · medium
Support clinical differential diagnosis of atypical Parkinsonian disorders using eye-movement abnormalities.
Eye movement analysis, including assessment of ocular motor signatures relevant to Parkinson's disease and atypical parkinsonism.
Listed by NeuroClues as a clinical differential-diagnosis area for atypical Parkinson.
The supplied review notes disease-specific ocular motor patterns, including saccadic hypometria in Parkinson's disease and vertical supranuclear gaze palsy or saccadic apraxia in atypical parkinsonism; no NeuroClues-specific validation result is provided.
Eye movement biomarkers for neurological disorders
approvedbiomarker · high
Use oculomotor measurements as biomarkers for diagnosis and monitoring of neurological disorders such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, parkinsonian syndromes, and concussion-related impairments.
Eye-tracking paradigms and neurological biomarker extraction from recorded eye movements.
CE-marked Class IIa medical device available for clinical neurological assessment.
The supplied material describes objective, reproducible biomarkers derived from eye movements; no quantitative clinical performance results are provided.
ICEBERG Cohort
exploratoryresearch program · medium
Conduct cohort-based research relevant to NeuroClues' neurological eye-tracking biomarker work.
Research agreement for a named cohort program; supplied material does not provide the cohort protocol details.
Research agreement concluded for the ICEBERG Cohort.
Longitudinal SCA2 and SCA7 biomarker cohort
exploratoryresearch program · medium
Identify longitudinal clinical, imaging, fluid, gait, oculomotor, and ophthalmologic biomarkers in preataxic and early ataxic spinocerebellar ataxia type 2 and 7 carriers.
One-year cohort study with baseline, 6-month, and 12-month assessments including neurologic, quality-of-life, orofacial motor, neuropsychological, ophthalmologic, gait, oculomotor, MRI, CSF, and blood measures.
2024 Neurology publication reported longitudinal biomarker changes over 1 year.
The study detected annual changes across MRI, clinical scores, gait parameters, retinal thickness, and orofacial motility; authors suggested these parameters could serve as potential endpoints for future therapeutic trials in the preataxic phase.
